Regulated information

Q3 2018 sales: €90.2 million Vetoquinol wins second prize for CSR in the Gaia Rating

In the first nine months of 2018, Vetoquinol recorded sales of €268.1 million, up 3.8% at constant exchange rates and 0.4% as reported.

Vetoquinol takes a major step towards digital innovation by acquiring an equity interest in Farmvet Systems Ltd

Vetoquinol, a leading global animal health company, has acquired a majority interest in Farmvet Systems Ltd. A thriving start-up based in Northern Ireland, Farmvet Systems digital know-how enables the strengthening of the role of the veterinary practitioner on cattle farms.

First half 2018 results

At its meeting on July 25, 2018, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2018 financial statements.

Vetoquinol publishes its half-yearly financial report relative to fiscal year 2018

Vetoquinol publishes its half-yearly financial report relative to fiscal year 2018

Combined ordinary and extraordinary general meeting May 29, 2018

The Combined Ordinary and Extraordinary General meeting was held on Tuesday May 29, 2018 in Lure, chaired by Etienne Frechin.

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2017 (french version)

The registration document of Vetoquinol relative to fiscal year 2017, including the annual financial report relative to fiscal year 2017, was filed with the Autorité des marchés financiers (“the AMF”) on April 23, 2018. 

Q1 2018 sales: €87.6M like-for-like growth up 5.6%, 0.4% as reported growth of essentials products: up 6.8% as reported

Vetoquinol posted Q1 2018 consolidated sales of €87.6 million, up 5.6% like for like and 0.4% as reported, compared to the same period last year. Negative currency impacts of 5.2% were mainly related to the US and Canadian dollars and the Indian rupee. 

Strong growth in all key financial indicators in 2017 ebit up 9.4% to €46.0 million net income - group share up 25.2% to €34.8 million

At its meeting on March 14, 2018, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited 2017 financial statements. 

2017 sales: €352.2 million 7.6% like-for-like growth in essentials products

The Vetoquinol Group posted sales of €352.2 million for the 2017 financial year, up 1.0% like-forlike. After a negative currency impact of 0.5%, mainly linked to the US and Canadian dollars, reported growth amounted to 0.5%.  

Vétoquinol markets CEFTIOCYL® and KEFLORIL® two new injectable antibiotics for livestock

Lure, December 15, 2010 – In line with recent announcements, Vétoquinol is
launching Ceftiocyl® and Kefloril®, two new injectable antibiotics for livestock.
The products are being brought to market by the Group and its subsidiaries in
both domestic and export markets.

Vétoquinol appoints RÉGIS VIMAL DU MONTEIL Group Finance and Legal Director

November 30, 2010 (Lure, France) – Vétoquinol has appointed Régis Vimal du Monteil as
Group Legal and Financial Director.

Vétoquinol registers its injectable Marbocyl® 2% and Marbocyl® 10% antibiotics in Japan

November 18, 2010 (Lure, France) – Vétoquinol has just obtained Marketing
Authorisation (MA) from Japanese drug authorities for its Marbocyl® 2% and
Marbocyl® 10% antibiotics for livestock, through collaboration with Meiji Seika
Kaisha, Ltd.

Strong Sales in the 3rd Quarter of 2010

Vétoquinol’s revenues for the third quarter of 2010 rose by 10.8%. This healthy rate of growth was attributable mainly to strong performance in the Group’s strategic regions and therapeutic segments.

Mise à disposition ou de consultation du rapport financier semestriel 2010 (french)

Le Rapport financier semestriel 2010 de Vétoquinol peut être consulté ou téléchargé sur
le site Internet de la société : www.vetoquinol.com, rubrique « Investisseurs & Journalistes ».

Strong Results in the first half of 2010

The Board of Directors of Vétoquinol, meeting on August 30, reviewed the group’s business and approved its interim 2010 financial statements.

Continued Sales Growth in the second Quarter of 2010

Vétoquinol recorded strong sales growth (+15.1%) in the first six months of 2010, driven mainly by an increase in organic growth.

BOREVE-D: Vétoquinol is participating in a project to raise awareness of the need to treat pain in cattle

June 30, 2010 (Lure, France) – Vétoquinol, in collaboration with two other veterinary laboratories, is participating in a project organised by the Syndicat de l’Industrie du Médicament Vétérinaire (SIMV) to raise awareness of the need to treat pain in cattle.

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2009 (french version)

The registration document of Vétoquinol relative to fiscal year 2009, including the annual financial report relative to fiscal year 2009, was registered with the Autorité des marchés financiers (“the AMF”) on April 22th, 2010.

Continued sales growth driven by sustained organic growth

April 22, 2010 (Lure, France) - Vétoquinol recorded a significant increase in sales in the first quarter of 2010, driven by sustained organic growth and the contribution of its Indian acquisition.

Departure of Pierre Konareff

April 14, 2010 (Lure, France) – The Vétoquinol Group today announces the departure of Pierre
Konareff, Group Director of Finance and Legal Affairs, because of differences concerning his
position in the Group. Pierre Konareff joined Vétoquinol in July 2008.

2009 annual earnings

March 31, 2010 – (Lure, France) – Vétoquinol’s Board of Directors, meeting on March 11, 2010, reviewed the Group’s business and approved its 2009 financial statements.

Redemption of tranche A bonds

February 26, 2010 (Lure, France) - Following the decision of Soparfin (family holding Etienne Frechin) not to convert the tranche A convertible bonds when they reach maturity on February 27, 2010, Vétoquinol has redeemed the bonds.

Strong growth in 2009 Revenues: +7.6%

January 20, 2010 (Lure, France) - Vétoquinol recorded strong sales growth in 2009, despite an unfavourable exchange rate effect. The strength in sales is explained to a large extent by the contribution of acquisitions in Italy and India and by the resumption of organic growth, which held firm in the second half of 2009 despite the continuing weakness in the general economy. Revenues increased in all therapeutic classes and all geographic regions.

VÉTOQUINOL and JANSSEN ANIMAL HEALTH finalize an agreement for the exclusive distribution of SUROLAN® in the United States

January 14, 2010 (Lure, France) – As part of its strategy of expanding its sales in the American market, Vétoquinol is pleased to announce an agreement with Janssen Animal Health to distribute Surolan® in the United States, following its approval by the FDA in December 2009. Surolan® is a leading example of Vétoquinol’s strategic focus on anti-infective agents and its success in this area. Surolan® has an excellent reputation in Europe, where it has been a great success.